drugset / Trial / NCT03875313
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose polymerase (PARP) inhibitor talazoparib in participants with advanced/metastatic solid tumors.
Timeline
- Start
- 2019-05-20
- Primary completion
- 2020-07-29
- Completion
- 2020-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CB-839 | Unknown | 600 mg | Oral |
| Subject | CB-839 | Unknown | 800 mg | Oral |
| Subject | Talazoparib | Small molecule | 1 mg | Oral |